FDA Panel Rejects Expanded Use of Prostate Drug


December 2, 2010

The New York Times

The question before the Food and Drug Administration advisory committee on Tuesday was path-breaking: Would it recommend that the labels of two drugs be changed to say that they can reduce a man’s risk of getting prostate cancer?

If the drugs were approved for that purpose, they would be only the second class of cancer-prevention drugs on the market — the first being drugs like tamoxifen that block estrogen and reduce the risk of breast cancer... Read More